Summary
This prediction ended on 01.11.18 with a price of €13.53. The prediction for Merus BV disappointed with a performance of -16.67%. stratec has 50% into this predictionPerformance without dividends (%)
| Name | 1w | 1m | 1y | 3y |
|---|---|---|---|---|
| Merus BV | - | - | - | - |
| iShares Core DAX® | 1,01 % | 2,70 % | 4,36 % | 51,69 % |
| iShares Nasdaq 100 | -6,47 % | -8,77 % | 18,00 % | 67,99 % |
| iShares Nikkei 225® | -6,52 % | -12,58 % | 40,91 % | 57,11 % |
| iShares S&P 500 | -2,72 % | -1,75 % | 16,97 % | 58,87 % |
Comments by stratec for this prediction
In the thread Merus BV diskutieren
Merus will yield meaningful clinical data in the near future.
A lucrative partnership was signed with Incyte last year for which they received $120 million upfront and a common share purchase of $80 million. Incyte in return received exclusive rights for up to 11 bispecific antibody research programs utilizing Merus' Biclonics technology, which included two preclinical immuno-oncology candidates.
The technology of Merus has the potential to be sufficiently differentiated from monoclonal antibodies due to improved tumor cell killing activity and lower toxicity.
(Laufzeit überschritten)